Payment for oncolytics in the United States: a history of buy and bill and proposals for reform.
University of Chicago Medicine; University of Chicago, Chicago, IL; Swedish Cancer Institute, Edmonds, WA; Texas Oncology-Methodist, Dallas; Center for Cancer and Blood Disorders, Fort Worth, TX; Medical Oncology and Hematology Associates, Des Moines, IA; and Sarah Cannon Cancer Center, Nashville, TN.
Blase N
BN
Polite
University of Chicago Medicine; University of Chicago, Chicago, IL; Swedish Cancer Institute, Edmonds, WA; Texas Oncology-Methodist, Dallas; Center for Cancer and Blood Disorders, Fort Worth, TX; Medical Oncology and Hematology Associates, Des Moines, IA; and Sarah Cannon Cancer Center, Nashville, TN jeffery.ward@swedish.org.
Jeffery C
JC
Ward
University of Chicago Medicine; University of Chicago, Chicago, IL; Swedish Cancer Institute, Edmonds, WA; Texas Oncology-Methodist, Dallas; Center for Cancer and Blood Disorders, Fort Worth, TX; Medical Oncology and Hematology Associates, Des Moines, IA; and Sarah Cannon Cancer Center, Nashville, TN.
John V
JV
Cox
University of Chicago Medicine; University of Chicago, Chicago, IL; Swedish Cancer Institute, Edmonds, WA; Texas Oncology-Methodist, Dallas; Center for Cancer and Blood Disorders, Fort Worth, TX; Medical Oncology and Hematology Associates, Des Moines, IA; and Sarah Cannon Cancer Center, Nashville, TN.
Roscoe F
RF
Morton
University of Chicago Medicine; University of Chicago, Chicago, IL; Swedish Cancer Institute, Edmonds, WA; Texas Oncology-Methodist, Dallas; Center for Cancer and Blood Disorders, Fort Worth, TX; Medical Oncology and Hematology Associates, Des Moines, IA; and Sarah Cannon Cancer Center, Nashville, TN.
John
J
Hennessy
University of Chicago Medicine; University of Chicago, Chicago, IL; Swedish Cancer Institute, Edmonds, WA; Texas Oncology-Methodist, Dallas; Center for Cancer and Blood Disorders, Fort Worth, TX; Medical Oncology and Hematology Associates, Des Moines, IA; and Sarah Cannon Cancer Center, Nashville, TN.
Ray D
RD
Page
University of Chicago Medicine; University of Chicago, Chicago, IL; Swedish Cancer Institute, Edmonds, WA; Texas Oncology-Methodist, Dallas; Center for Cancer and Blood Disorders, Fort Worth, TX; Medical Oncology and Hematology Associates, Des Moines, IA; and Sarah Cannon Cancer Center, Nashville, TN.
Rena M
RM
Conti
D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D003132:Commerce; D017046:Cost Savings; D016527:Drug Costs; D017050:Episode of Care; D018166:Health Care Reform; D006291:Health Policy / Q000191:economics; D006801:Humans; D006278:Medicare / Q000191:economics; D009369:Neoplasms / Q000188:drug therapy / Q000191:economics*; D012051:Reimbursement Mechanisms / Q000191:economics; D014481:United States
D000970:Antineoplastic Agents